- Home
- BMRN vs NIO Comparison
BMRN vs NIO Comparison
Compare BMRN & NIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | NIO |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 11.7B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BMRN | NIO |
|---|---|---|
| Price | $56.93 | $4.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 9 |
| Target Price | ★ $90.15 | $6.73 |
| AVG Volume (30 Days) | 2.0M | ★ 46.2M |
| Earning Date | 02-18-2026 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.53 | N/A |
| EPS | ★ 2.68 | N/A |
| Revenue | $3,094,001,000.00 | ★ $10,189,444,895.00 |
| Revenue This Year | $13.42 | $33.27 |
| Revenue Next Year | $10.81 | $50.39 |
| P/E Ratio | $20.97 | ★ N/A |
| Revenue Growth | 12.39 | ★ 14.90 |
| 52 Week Low | $50.76 | $3.02 |
| 52 Week High | $73.51 | $8.02 |
Technical Indicators
Market Signals| Indicator | BMRN | NIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 40.32 |
| Support Level | $54.07 | $4.52 |
| Resistance Level | $58.33 | $4.90 |
| Average True Range (ATR) | 1.68 | 0.16 |
| MACD | -0.30 | 0.01 |
| Stochastic Oscillator | 36.02 | 11.54 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.